Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds.

Autor: Meyer M; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France. maxence.meyer@chru-strasbourg.fr., Constancias F; Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland., Worth C; Nuffield Department of Rheumatology, Orthopaedics and Musculosckeletal Sciences, University of Oxford, Oxford, UK., Meyer A; COVID Vaccination Center, Offenburg, Germany., Muller M; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France., Boussuge A; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France., Kaltenbach G; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France., Schmitt E; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France., Chayer S; Department of Clinical Research and Innovations, University Hospitals of Strasbourg, Strasbourg, France., Velay A; Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.; INSERM, UMR_S1109, LabEx TRANSPLANTEX, Research Center for Immunology and Hematology, Faculty of Medicine, University Hospital Federation (FHU) OMICARE, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, Strasbourg, France., Vogel T; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France., Fafi-Kremer S; Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.; INSERM, UMR_S1109, LabEx TRANSPLANTEX, Research Center for Immunology and Hematology, Faculty of Medicine, University Hospital Federation (FHU) OMICARE, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, Strasbourg, France., Karcher P; Department of Geriatric, University Hospitals of Strasbourg, 83 rue Himmerich, 67000, Strasbourg, France.
Jazyk: angličtina
Zdroj: GeroScience [Geroscience] 2022 Jun; Vol. 44 (3), pp. 1229-1240. Date of Electronic Publication: 2022 Apr 08.
DOI: 10.1007/s11357-022-00546-y
Abstrakt: The objectives of this study were to assess the dynamics of the SARS-CoV-2 anti-RBD-IgG response over time among older people after COVID-19 infection or vaccination and its comparison with indicative levels of protection. Geriatric patients with SARS-CoV-2 serological test results were included and divided into three groups. A vaccine group (n = 34), a group of natural COVID-19 infection (n = 32), and a group who contracted COVID-19 less than 15 days after the first injection (n = 17). Eighty-three patients were included; the median age with IQR was 87 (81-91) years. In the vaccine group at 1 month since the first vaccination, the median titer of anti-RBD-IgG was 620 (217-1874) BAU/ml with 87% of patients above the theoretical protective threshold of 141 BAU/ml according to Dimeglio et al. (J Infec. 84(2):248-88, [7]). Seven months after the first vaccination, this titer decreased to 30 (19-58) BAU/ml with 9.5% of patients > 141 BAU/ml. In the natural COVID-19 infection group, at 1 month since the date of first symptom onset, the median titer was 798 (325-1320) BAU/ml with 86.7% of patients > 141 BAU/ml and fell to 88 (37-385) with 42.9% of patients > 141 BAU/ml at 2 months. The natural infection group was vaccinated 3 months after the infection. Five months after the vaccination cycle, the median titer was 2048 (471-4386) BAU/ml with 83.3% of patients > 141 BAU/ml. This supports the clinical results describing the decrease in vaccine protection over time and suggests that vaccination after infection can maintain significantly higher antibody titer levels for a prolonged period of time.
(© 2022. The Author(s), under exclusive licence to American Aging Association.)
Databáze: MEDLINE
Externí odkaz: